Interactions with Antiretroviral Drugs

Charts reviewed February 2019. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

		PROTEASE INHIBITORS												NNRTIs						NRTIs									OTHER						
		ATV Alone	ATV/cobi	ATV + r	DRV/cobi	DRV/c/F/TAF	DRV + r	FPV	IDV	LPV	RTV	SQV	TPV	DOR	DOR/ 3TC/TDF	EFV	ETV	NVP	RPV	RPV/ FTC/TAF	ABC	ddI	FTC	FTC/TAF	FTC/TDF	3TC	d4T	TDF	ZDV	BIC/F/TAF	DTG	DTG/RPV	E/C/F/TAF	E/C/F/TDF	Ibalizumab	MVC	RAL
Protease Inhibitors	Atazanavir alone		●	●	●	●	◆	■	●	■	■	●	●	△	●	●	●	●	◆	■	◆	■	◆	■	●	◆	◆	●	◆	●	△	■	■	■	◆	■	△
	Atazanavir/cobicistat	●		●	●	●	●	●	●	●	●	●	●	△	■	●	●	●	◆	■	◆	■	◆	■	■	◆	◆	■	◆	●	△	■	●	●	◆	■	△
	Atazanavir + ritonavir	●	●		●	●	●	●	●	■	●	●	●	△	■	●	■	●	◆	■	◆	■	◆	■	■	◆	◆	■	◆	●	△	■	●	●	◆	■	△
	Darunavir/cobicistat	●	●	●		●	●	●	●	●	●	●	●	△	■	●	●	●	◆	●	◆	■	◆	■	■	◆	◆	■	◆	●	■	◆	■	●	●	◆	■	◆
	Darunavir/Cobi/F/TAF	●	●	●	●		●	●	●	●	●	●	●	■	●	●	●	●	■	●	●	●	●	●	●	●	●	●	●	●	■	■	●	●	■	■	■
	Darunavir + ritonavir	◆	●	●	●	●	F	●	■	●	■	●	●	△	■	■	◆	◆	◆	●	◆	■	◆	■	■	◆	◆	■	◆	●	■	◆	■	●	●	◆	■	◆
	Fosamprenavir	■	●	●	●	●	●	O	◆	■	■	■	●	△	■	■	●	◆	◆	●	◆	◆	◆	■	■	◆	◆	■	◆	●	■	●	●	●	◆	■	■
	Indinavir	●	●	●	●	●	■	◆	R	■	■	■	●	△	■	■	●	■	◆	●	◆	■	◆	■	■	◆	◆	■	◆	●	■	◆	■	●	◆	■	◆
	Lopinavir	■	●	■	●	●	●	■	■		■	●	●	△	■	■	◆	■	◆	●	△	■	◆	■	■	◆	◆	■	◆	●	■	◆	■	●	◆	■	◆
	Ritonavir	■	●	●	●	●	■	■	■	■		■	■	△	■	■	■	◆	◆	●	◆	■	◆	■	■	◆	◆	■	◆	■	■	◆	■	●	◆	■	◆
	Saquinavir	●	●	●	●	●	●	■	■	●	■	P	●	△	■	■	◆	■	◆	●	◆	■	◆	■	■	◆	◆	■	◆	●	■	◆	●	●	◆	■	◆
	Tipranavir	●	●	●	●	●	●	●	●	●	■	●	E	△	■	◆	●	◆	●	◆	●	■	◆	●	■	◆	◆	■	◆	●	■	●	●	●	◆	◆	■
NNRTIs	Doravirine	△	△	△	△	■	△	△	△	△	△	△	△	R	■	●	●	●	●	●	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●	△	△	◆	◆	◆
	Doravirine/3TC/TDF	●	■	■	■	●	■	■	■	■	■	■	■	■	S	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	■	●	●	●	■	■	■
	Efavirenz	●	●	●	●	●	■	■	■	■	■	■	◆	●	●	O	●	●	●	●	◆	◆	◆	◆	◆	◆	◆	◆	◆	●	■	●	●	◆	■	◆
	Etravirine	●	●	■	●	●	◆	●	●	◆	■	◆	●	●	●	●	N	●	●	●	◆	◆	◆	◆	◆	◆	◆	◆	◆	●	■	●	●	◆	■	◆
	Nevirapine	●	●	●	●	●	◆	◆	■	■	◆	■	◆	●	●	●	●	A	●	●	◆	◆	◆	◆	◆	◆	◆	◆	◆	●	■	●	●	◆	◆	◆	◆
	Rilpivirine	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	●	●	●	●	●	●	L	●	◆	■	◆	◆	◆	◆	◆	◆	◆	■	◆	■	■	◆	◆	◆	◆
	Rilpivirine/FTC/TAF	■	■	■	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●		●	●	●	●	●	●	●	●	●	●	■	●	●	◆	■	■
NRTIs	Abacavir (ABC)	◆	◆	◆	◆	●	◆	◆	◆	△	◆	◆	●	◆	●	◆	◆	◆	◆	●	U	◆	◆	◆	△	◆	◆	◆	◆	●	◆	■	●	●	◆	◆	◆
	Didanosine (ddI)	■	■	■	■	●	■	◆	■	■	■	■	■	◆	●	◆	◆	◆	■	●	◆	S	◆	■	●	■	●	●	◆	●	◆	●	●	●	◆	◆	◆
	Emtricitabine (FTC)	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	●	◆	◆	E	●	●	●	◆	◆	◆	●	◆	■	●	●	◆	◆	◆
	Emtricitabine/TAF	■	■	■	■	●	■	■	■	■	■	■	●	◆	●	◆	◆	◆	◆	●	◆	■	●		●	●	●	◆	●	●	◆	■	●	●	◆	◆	◆
	Emtricitabine/TDF	●	■	■	■	●	■	■	■	■	■	■	■	◆	●	◆	◆	◆	◆	●	△	●	●	●		●	●	◆	●	●	◆	■	●	●	◆	◆	◆
	Lamivudine (3TC)	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	●	◆	■	●	●	●	O	◆	◆	◆	●	◆	■	●	●	◆	◆	◆
	Stavudine (d4T)	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	N	◆	●	●	◆	●	●	●	◆	◆	◆
	Tenofovir-DF (TDF)	●	■	■	■	●	■	■	■	■	■	■	■	◆	●	◆	◆	◆	◆	●	◆	●	◆	●	●	◆	◆	L	◆	●	◆	■	●	●	◆	◆	◆
	Zidovudine (AZT/ZDV)	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	●	Y	●	◆	■	●	●	◆	◆	◆
Other	Bictegravir/F/TAF	●	●	●	■	●	■	●	●	●	■	●	●	◆	●	●	●	●	■	●	●	●	●	●	●	●	●	●	●		●	●	●	◆	■	●
	Dolutegravir	△	△	△	◆	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	■	◆	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	●		●	●	●	◆	◆	◆
	Dolutegravir/Rilpivirine	■	■	■	■	■	■	●	■	■	■	●	●	●	●	●	●	●	●	●	■	●	■	■	■	■	●	■	■	●	●		●	●	◆	■	●
	Elvitegravir/Cobi/F/TAF	■	●	●	●	●	●	●	●	●	●	●	●	△	●	●	●	●	■	●	●	●	●	●	●	●	●	●	●	●	●	●		●	◆	■	●
	Elvitegravir/Cobi/F/TDF	■	●	●	●	●	●	●	●	●	●	●	●	△	●	●	●	●	■	●	●	●	●	●	●	●	●	●	●	●	●	●	●		◆	■	●
	Enfuvirtide (T20)	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	■	◆	●	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●	◆	●	●	◆		◆	◆
	Ibalizumab	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆		◆	◆
	Maraviroc	■	■	■	■	■	■	■	■	■	■	■	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	■	■	■	◆		◆
	Raltegravir	△	△	△	◆	■	◆	■	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	●	◆	●	●	●	◆	◆	

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity - additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option.

Co-formulations

Atripla®	Efavirenz + Emtricitabine + Tenofovir-DF
Biktarvy®	Bictegravir + Emtricitabine + Tenofovir alafenamide
Combivir®	Lamivudine + Zidovudine
Complera®	Emtricitabine + Rilpivirine + Tenofovir-DF
Delstrigo®	Doravirine + Lamivudine + Tenofovir-DF
Descovy®	Emtricitabine + Tenofovir alafenamide
Eviplera®	Emtricitabine + Rilpivirine + Tenofovir-DF
Evotaz®	Atazanavir + Cobicistat
Genvoya®	Elvitegravir + Cobicistat + Emtricitabine + Tenofovir alafenamide
Juluca®	Dolutegravir + Rilpivirine
Kivexa®	Abacavir + Lamivudine
Odefsey®	Emtricitabine + Rilpivirine + Tenofovir alafenamide
Prezcobix®	Darunavir + Cobicistat
Rezolsta®	Darunavir + Cobicistat
Symtuza®	Darunavir + Cobicistat + Emtricitabine + Tenofovir alafenamide
Stribild®	Elvitegravir + Cobicistat + Emtricitabine + Tenofovir-DF
Triumeq®	Abacavir + Lamivudine + Dolutegravir
Trizivir®	Abacavir + Lamivudine + Zidovudine
Truvada®	Emtricitabine + Tenofovir-DF

Key to abbreviations

ATV	Atazanavir (Reyataz®)
ATV/cobi	Atazanavir/Cobicistat (Evotaz®)
ATV + r	Atazanavir + Ritonavir (Reyataz® + Norvir®)
DRV/cobi	Darunavir/Cobicistat (Rezolsta®, Prezcobix®)
DRV/c/FTAF	Darunavir, cobicistat, emtricitabine, tenofovir alafenamide (Symtuza®)
DRV + r	Darunavir + Ritonavir (Prezista® + Norvir®)
FPV	Fosamprenavir (Telzir®, Lexiva®)
IDV	Indinavir (Crixivan®)
LPV	Lopinavir (Kaletra®)
RTV	Ritonavir (Norvir®)
SQV	Saquinavir (Invirase®)
TPV	Tipranavir (Aptivus®)

DOR	Doravirine (Pifeltro®)
DOR + 3TC/TDF	Doravirine/Lamivudine/ Tenofovir-DF (Delstrigo®)
EFV	Efavirenz (Sustiva®, Stocrin®)
ETV	Etravirine (Intelence®)
NVP	Nevirapine (Viramune®)
RPV	Rilpivirine (Edurant®)

ABC	Abacavir (Ziagen®)
ddI	Didanosine (Videx®, Videx-EC®)
FTC	Emtricitabine (Emtriva®)
3TC	Lamivudine (Epivir®)
d4T	Stavudine (Zerit®)
TAF	Tenofovir alafenamide
TDF	Tenofovir disoproxil fumarate (Viread®)
ZDV	Zidovudine (Retrovir®)

BIC/F/TAF	Bictegravir + Emtricitabine + Tenofovir alafenamide (Biktarvy®)
DTG	Dolutegravir (Tivicay®)
E/C/F/TAF	Elvitegravir + Cobicistat + Emtricitabine + Tenofovir alafenamide (Genvoya®)
E/C/F/TDF	Elvitegravir + Cobicistat + Emtricitabine+ Tenofovir disoproxil fumarate (Stribild®)
Ibalizumab	Ibalizumab-uiyk (Trogarzo®)
MVC	Maraviroc (Celsentri®, Selzentry®)
RAL	Raltegravir (Isentress®)

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.